World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
34396
World Ranking
12101
National Ranking
6209

Overview

Elizabeth A. Mittendorf is affiliated with Brigham and Women's Hospital in the United States. Their research primarily focuses on the fields of medicine and biochemistry, genetics, and molecular biology, with significant contributions to oncology and cancer research. Subfields in which they have an extensive publication record include pulmonary and respiratory medicine, pathology and forensic medicine, as well as radiology, nuclear medicine, and imaging.

Their scientific inquiry centers notably on topics related to breast cancer treatment studies, cancer immunotherapy and biomarkers, HER2/EGFR in cancer research, advanced breast cancer therapies, breast lesions and carcinomas, cancer genomics and diagnostics, and cancer treatment and pharmacology.

Frequent co-authors in their publications include:

  • Tari A. King
  • Sara M. Tolaney
  • Nabihah Tayob
  • Nancy U. Lin
  • Eric P. Winer

Their work has appeared repeatedly in several prominent journals, including:

  • Cancer Research
  • Annals of Surgical Oncology
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Breast Cancer Research and Treatment

Key recent publications by Elizabeth A. Mittendorf include:

  • Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial, 2020, The Lancet
  • Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche, 2022, Cell
  • Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer, 2020, Nature Cancer
  • Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer, 2022, JAMA Oncology
  • Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer, 2020, Cancer Cell

Best Publications

  • Glypican-1 identifies cancer exosomes and detects early pancreatic cancer

    Sonia A. Melo;Linda B. Luecke;Christoph Kahlert;Agustin F. Fernandez

  • Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial

    Judy C. Boughey;Vera J. Suman;Elizabeth A. Mittendorf;Gretchen M. Ahrendt

  • PD-L1 Expression in Triple-Negative Breast Cancer

    Elizabeth A Mittendorf;Anne V Philips;Funda Meric-Bernstam;Na Qiao

  • Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

    Armando E. Giuliano;James L. Connolly;Stephen B. Edge;Elizabeth A. Mittendorf

  • Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection

    Abigail S. Caudle;Wei T. Yang;Savitri Krishnamurthy;Elizabeth A. Mittendorf

  • Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

    Elizabeth A Mittendorf;Hong Zhang;Carlos H Barrios;Shigehira Saji

  • Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.

    Jong-Ho Cha;Wen-Hao Yang;Weiya Xia;Yongkun Wei

  • Classification of current anticancer immunotherapies

    Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué

  • Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).

    Judy C. Boughey;Karla V. Ballman;Huong T. Le-Petross;Linda M. McCall

  • Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

    Naoki Niikura;Jun Liu;Naoki Hayashi;Elizabeth Ann Mittendorf

  • Current Landscape of Immunotherapy in Breast Cancer: A Review

    Sylvia Adams;Margaret E. Gatti-Mays;Kevin Kalinsky;Larissa A. Korde

  • Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients.

    Kelly K. Hunt;Min Yi;Elizabeth A. Mittendorf;Cynthia Guerrero

  • Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial

    Judy C. Boughey;Linda M. McCall;Karla V. Ballman;Elizabeth A. Mittendorf

  • Loss of HER2 Amplification Following Trastuzumab-based Neoadjuvant Systemic Therapy and Survival Outcomes

    Elizabeth A. Mittendorf;Yun Wu;Maurizio Scaltriti;Funda Meric-Bernstam

  • Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

    Elizabeth Ann Mittendorf;G. T. Clifton;J. P. Holmes;E. Schneble

  • Which threshold for ER positivity? a retrospective study based on 9639 patients

    M. Yi;Lei Huo;Kimberly Brooke Koenig;Elizabeth Ann Mittendorf

  • Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

    George E. Peoples;George E. Peoples;Jarrod P. Holmes;Jarrod P. Holmes;Matthew T. Hueman;Matthew T. Hueman;Elizabeth A. Mittendorf

  • Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated With Neoadjuvant Therapy

    Jacqueline S. Jeruss;Elizabeth A. Mittendorf;Susan L. Tucker;Ana M. Gonzalez-Angulo

  • Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

    Elizabeth Ann Mittendorf;Guy T. Clifton;Jarrod P. Holmes;Kevin S. Clive

  • Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance)

    Judy C. Boughey;Karla V. Ballman;Kelly K. Hunt;Linda M. McCall

Frequent Co-Authors

Kelly K. Hunt
Kelly K. Hunt The University of Texas MD Anderson Cancer Center
Henry Mark Kuerer
Henry Mark Kuerer The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center
Alastair M. Thompson
Alastair M. Thompson Baylor College of Medicine
Gildy Babiera
Gildy Babiera The University of Texas MD Anderson Cancer Center
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Sara M. Tolaney
Sara M. Tolaney Harvard University
Eric P. Winer
Eric P. Winer Yale University
Jeffrey J. Molldrem
Jeffrey J. Molldrem The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine often involves exploring different educational paths and specializations. Many students start by looking for affordable options, such as the cheapest bsn programs online, which offer a convenient and cost-effective way to enter the nursing profession.

For registered nurses aiming to advance their education, there are also flexible cheapest bsn programs available fully online. These programs are designed for working professionals and can open doors to more specialized roles or leadership positions within healthcare.

If you’re considering a non-traditional route into advanced nursing, online msn programs for non nurses provide a fast track to earn a master’s degree even if you do not have a nursing background. These programs address the growing need for qualified healthcare providers in the USA.

Those interested in the highest levels of nursing education and leadership might explore phd nursing programs, which can lead to opportunities in research, academia, and policy-making. Online programs in this field offer flexible study options for aspiring nurse leaders.

Best Scientists Citing Elizabeth A. Mittendorf

Trending Scientists

Recently Published Articles